Q1 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other PluvictoⓇ - Radioligand therapy target PSMA PluvictoⓇ - Radioligand therapy target PSMA NCT04689828 PSMAfore (CAAA617B12302) NCT04720157 PSMAddition (CAAA617C12301) Metastatic hormone sensitive prostate cancer Indication Phase Metastatic castration-resistant prostate cancer, pre-taxane Phase 3 Indication Phase Phase 3 Patients 450 Patients 1126 Primary Radiographic Progression Free Survival (rPFS) Primary Outcome Outcome Measures Measures Arms Arms Intervention Intervention Target Patients Arm 1: Participants will receive 7.4 GBq (200 mCi) +/- 10% 177 Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used Arm 2: For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used mCRPC patients that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings Primary Analysis: 2022 (actual) Readout Milestone(s) Final Analysis: 2025 Publication TBD 77 Investor Relations | Q1 2023 Results Radiographic Progression Free Survival (rPFS) Arm 1: 177Lu-PSMA-617 Participant will receive 7.4 GBq (+/- 10%) 177 Lu-PSMA- 617, once every 6 weeks for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Arm 2: For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) Target Patients Readout Milestone(s) Publication Primary Analysis: 2024 TBD NOVARTIS | Reimagining Medicine

View entire presentation